John J. Miles
Australian Institute of Tropical Health and Medicine
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by John J. Miles.
Nature Immunology | 2018
Kwok Soon Wun; Josephine F. Reijneveld; Tan Yun Cheng; Kristin Ladell; Adam P. Uldrich; Jérôme Le Nours; Kelly Louise Miners; James Edward McLaren; Emma J. Grant; Oscar L. Haigh; Thomas S. Watkins; Sara Suliman; Sarah Iwany; Judith Jimenez; Roger Calderon; Kattya L. Tamara; Segundo R. Leon; Megan Murray; Jacob A. Mayfield; John D. Altman; Anthony W. Purcell; John J. Miles; Dale I. Godfrey; Stephanie Gras; David A. Price; Ildiko Van Rhijn; D. Branch Moody; Jamie Rossjohn
The hallmark function of αβ T cell antigen receptors (TCRs) involves the highly specific co-recognition of a major histocompatibility complex molecule and its carried peptide. However, the molecular basis of the interactions of TCRs with the lipid antigen–presenting molecule CD1c is unknown. We identified frequent staining of human T cells with CD1c tetramers across numerous subjects. Whereas TCRs typically show high specificity for antigen, both tetramer binding and autoreactivity occurred with CD1c in complex with numerous, chemically diverse self lipids. Such extreme polyspecificity was attributable to binding of the TCR over the closed surface of CD1c, with the TCR covering the portal where lipids normally protrude. The TCR essentially failed to contact lipids because they were fully seated within CD1c. These data demonstrate the sequestration of lipids within CD1c as a mechanism of autoreactivity and point to small lipid size as a determinant of autoreactive T cell responses.CD1 molecules present diverse lipid ligands to TCRs expressed by NKT cells. Rossjohn, Moody and colleagues show a unique form of autoreactivity with human CD1c molecules, whereby TCRs recognize a closed conformation of CD1c molecules, which are loaded with a diverse array of ‘headless’ glycolipids.
elly Tie Knit Dress Ribbed dee Strap 75d7q & trexyourex.com | 2018
John J. Miles; Mai Ping Tan; Garry Dolton; Sarah A.E. Galloway; Bruno Laugel; Mathew Clement; Julia Makinde; Kristin Ladell; Katherine K. Matthews; Thomas S. Watkins; Katie Tungatt; Yide Wong; Han Siean Lee; Richard J. Clark; Johanne M. Pentier; Meriem Attaf; Anya Lissina; Ann Ager; Awen Gallimore; Pierre J. Rizkallah; Stephanie Gras; Jamie Rossjohn; Scott R. Burrows; David K. Cole; David A. Price; Andrew K. Sewell
Polypeptide vaccines effectively activate human T cells but suffer from poor biological stability, which confines both transport logistics and in vivo therapeutic activity. Synthetic biology has the potential to address these limitations through the generation of highly stable antigenic “mimics” using subunits that do not exist in the natural world. We developed a platform based on D–amino acid combinatorial chemistry and used this platform to reverse engineer a fully artificial CD8+ T cell agonist that mirrored the immunogenicity profile of a native epitope blueprint from influenza virus. This nonnatural peptide was highly stable in human serum and gastric acid, reflecting an intrinsic resistance to physical and enzymatic degradation. In vitro, the synthetic agonist stimulated and expanded an archetypal repertoire of polyfunctional human influenza virus–specific CD8+ T cells. In vivo, specific responses were elicited in naive humanized mice by subcutaneous vaccination, conferring protection from subsequent lethal influenza challenge. Moreover, the synthetic agonist was immunogenic after oral administration. This proof-of-concept study highlights the power of synthetic biology to expand the horizons of vaccine design and therapeutic delivery.
amp; Alexis Gray Flare Fit Dress Alton Z4AwqHZ & trexyourex.com | 2018
John J. Miles; Mai Ping Tan; Garry Dolton; Sarah A.E. Galloway; Bruno Laugel; Mathew Clement; Julia Makinde; Kristin Ladell; Katherine K. Matthews; Thomas S. Watkins; Katie Tungatt; Yide Wong; Han Siean Lee; Richard J. Clark; Johanne M. Pentier; Meriem Attaf; Anya Lissina; Ann Ager; Awen Gallimore; Pierre J. Rizkallah; Stephanie Gras; Jamie Rossjohn; Scott R. Burrows; David K. Cole; David A. Price; Andrew K. Sewell
Polypeptide vaccines effectively activate human T cells but suffer from poor biological stability, which confines both transport logistics and in vivo therapeutic activity. Synthetic biology has the potential to address these limitations through the generation of highly stable antigenic “mimics” using subunits that do not exist in the natural world. We developed a platform based on D–amino acid combinatorial chemistry and used this platform to reverse engineer a fully artificial CD8+ T cell agonist that mirrored the immunogenicity profile of a native epitope blueprint from influenza virus. This nonnatural peptide was highly stable in human serum and gastric acid, reflecting an intrinsic resistance to physical and enzymatic degradation. In vitro, the synthetic agonist stimulated and expanded an archetypal repertoire of polyfunctional human influenza virus–specific CD8+ T cells. In vivo, specific responses were elicited in naive humanized mice by subcutaneous vaccination, conferring protection from subsequent lethal influenza challenge. Moreover, the synthetic agonist was immunogenic after oral administration. This proof-of-concept study highlights the power of synthetic biology to expand the horizons of vaccine design and therapeutic delivery.
Z Zella Waist Leggings High By Daily r5F14cWgr & trexyourex.com | 2018
John J. Miles; Mai Ping Tan; Garry Dolton; Sarah A.E. Galloway; Bruno Laugel; Mathew Clement; Julia Makinde; Kristin Ladell; Katherine K. Matthews; Thomas S. Watkins; Katie Tungatt; Yide Wong; Han Siean Lee; Richard J. Clark; Johanne M. Pentier; Meriem Attaf; Anya Lissina; Ann Ager; Awen Gallimore; Pierre J. Rizkallah; Stephanie Gras; Jamie Rossjohn; Scott R. Burrows; David K. Cole; David A. Price; Andrew K. Sewell
Polypeptide vaccines effectively activate human T cells but suffer from poor biological stability, which confines both transport logistics and in vivo therapeutic activity. Synthetic biology has the potential to address these limitations through the generation of highly stable antigenic “mimics” using subunits that do not exist in the natural world. We developed a platform based on D–amino acid combinatorial chemistry and used this platform to reverse engineer a fully artificial CD8+ T cell agonist that mirrored the immunogenicity profile of a native epitope blueprint from influenza virus. This nonnatural peptide was highly stable in human serum and gastric acid, reflecting an intrinsic resistance to physical and enzymatic degradation. In vitro, the synthetic agonist stimulated and expanded an archetypal repertoire of polyfunctional human influenza virus–specific CD8+ T cells. In vivo, specific responses were elicited in naive humanized mice by subcutaneous vaccination, conferring protection from subsequent lethal influenza challenge. Moreover, the synthetic agonist was immunogenic after oral administration. This proof-of-concept study highlights the power of synthetic biology to expand the horizons of vaccine design and therapeutic delivery.
Yoga Pant James Riding Perse Perse James xrrwWqXtS & trexyourex.com | 2018
John J. Miles; Mai Ping Tan; Garry Dolton; Sarah A.E. Galloway; Bruno Laugel; Mathew Clement; Julia Makinde; Kristin Ladell; Katherine K. Matthews; Thomas S. Watkins; Katie Tungatt; Yide Wong; Han Siean Lee; Richard J. Clark; Johanne M. Pentier; Meriem Attaf; Anya Lissina; Ann Ager; Awen Gallimore; Pierre J. Rizkallah; Stephanie Gras; Jamie Rossjohn; Scott R. Burrows; David K. Cole; David A. Price; Andrew K. Sewell
Polypeptide vaccines effectively activate human T cells but suffer from poor biological stability, which confines both transport logistics and in vivo therapeutic activity. Synthetic biology has the potential to address these limitations through the generation of highly stable antigenic “mimics” using subunits that do not exist in the natural world. We developed a platform based on D–amino acid combinatorial chemistry and used this platform to reverse engineer a fully artificial CD8+ T cell agonist that mirrored the immunogenicity profile of a native epitope blueprint from influenza virus. This nonnatural peptide was highly stable in human serum and gastric acid, reflecting an intrinsic resistance to physical and enzymatic degradation. In vitro, the synthetic agonist stimulated and expanded an archetypal repertoire of polyfunctional human influenza virus–specific CD8+ T cells. In vivo, specific responses were elicited in naive humanized mice by subcutaneous vaccination, conferring protection from subsequent lethal influenza challenge. Moreover, the synthetic agonist was immunogenic after oral administration. This proof-of-concept study highlights the power of synthetic biology to expand the horizons of vaccine design and therapeutic delivery.
Workshop Terry Dress Hooded French Short Sleeve q8xaAqZ7n & trexyourex.com | 2018
John J. Miles; Mai Ping Tan; Garry Dolton; Sarah A.E. Galloway; Bruno Laugel; Mathew Clement; Julia Makinde; Kristin Ladell; Katherine K. Matthews; Thomas S. Watkins; Katie Tungatt; Yide Wong; Han Siean Lee; Richard J. Clark; Johanne M. Pentier; Meriem Attaf; Anya Lissina; Ann Ager; Awen Gallimore; Pierre J. Rizkallah; Stephanie Gras; Jamie Rossjohn; Scott R. Burrows; David K. Cole; David A. Price; Andrew K. Sewell
Polypeptide vaccines effectively activate human T cells but suffer from poor biological stability, which confines both transport logistics and in vivo therapeutic activity. Synthetic biology has the potential to address these limitations through the generation of highly stable antigenic “mimics” using subunits that do not exist in the natural world. We developed a platform based on D–amino acid combinatorial chemistry and used this platform to reverse engineer a fully artificial CD8+ T cell agonist that mirrored the immunogenicity profile of a native epitope blueprint from influenza virus. This nonnatural peptide was highly stable in human serum and gastric acid, reflecting an intrinsic resistance to physical and enzymatic degradation. In vitro, the synthetic agonist stimulated and expanded an archetypal repertoire of polyfunctional human influenza virus–specific CD8+ T cells. In vivo, specific responses were elicited in naive humanized mice by subcutaneous vaccination, conferring protection from subsequent lethal influenza challenge. Moreover, the synthetic agonist was immunogenic after oral administration. This proof-of-concept study highlights the power of synthetic biology to expand the horizons of vaccine design and therapeutic delivery.
Velvet One Parker Shoulder Rima Blouse qatfAwx7z & trexyourex.com | 2018
John J. Miles; Mai Ping Tan; Garry Dolton; Sarah A.E. Galloway; Bruno Laugel; Mathew Clement; Julia Makinde; Kristin Ladell; Katherine K. Matthews; Thomas S. Watkins; Katie Tungatt; Yide Wong; Han Siean Lee; Richard J. Clark; Johanne M. Pentier; Meriem Attaf; Anya Lissina; Ann Ager; Awen Gallimore; Pierre J. Rizkallah; Stephanie Gras; Jamie Rossjohn; Scott R. Burrows; David K. Cole; David A. Price; Andrew K. Sewell
Polypeptide vaccines effectively activate human T cells but suffer from poor biological stability, which confines both transport logistics and in vivo therapeutic activity. Synthetic biology has the potential to address these limitations through the generation of highly stable antigenic “mimics” using subunits that do not exist in the natural world. We developed a platform based on D–amino acid combinatorial chemistry and used this platform to reverse engineer a fully artificial CD8+ T cell agonist that mirrored the immunogenicity profile of a native epitope blueprint from influenza virus. This nonnatural peptide was highly stable in human serum and gastric acid, reflecting an intrinsic resistance to physical and enzymatic degradation. In vitro, the synthetic agonist stimulated and expanded an archetypal repertoire of polyfunctional human influenza virus–specific CD8+ T cells. In vivo, specific responses were elicited in naive humanized mice by subcutaneous vaccination, conferring protection from subsequent lethal influenza challenge. Moreover, the synthetic agonist was immunogenic after oral administration. This proof-of-concept study highlights the power of synthetic biology to expand the horizons of vaccine design and therapeutic delivery.
Vanity Room Midi Neck Dress Knit Mock Popover H7w8a & trexyourex.com | 2018
John J. Miles; Mai Ping Tan; Garry Dolton; Sarah A.E. Galloway; Bruno Laugel; Mathew Clement; Julia Makinde; Kristin Ladell; Katherine K. Matthews; Thomas S. Watkins; Katie Tungatt; Yide Wong; Han Siean Lee; Richard J. Clark; Johanne M. Pentier; Meriem Attaf; Anya Lissina; Ann Ager; Awen Gallimore; Pierre J. Rizkallah; Stephanie Gras; Jamie Rossjohn; Scott R. Burrows; David K. Cole; David A. Price; Andrew K. Sewell
Polypeptide vaccines effectively activate human T cells but suffer from poor biological stability, which confines both transport logistics and in vivo therapeutic activity. Synthetic biology has the potential to address these limitations through the generation of highly stable antigenic “mimics” using subunits that do not exist in the natural world. We developed a platform based on D–amino acid combinatorial chemistry and used this platform to reverse engineer a fully artificial CD8+ T cell agonist that mirrored the immunogenicity profile of a native epitope blueprint from influenza virus. This nonnatural peptide was highly stable in human serum and gastric acid, reflecting an intrinsic resistance to physical and enzymatic degradation. In vitro, the synthetic agonist stimulated and expanded an archetypal repertoire of polyfunctional human influenza virus–specific CD8+ T cells. In vivo, specific responses were elicited in naive humanized mice by subcutaneous vaccination, conferring protection from subsequent lethal influenza challenge. Moreover, the synthetic agonist was immunogenic after oral administration. This proof-of-concept study highlights the power of synthetic biology to expand the horizons of vaccine design and therapeutic delivery.
Vanity Maxi Waist Smocked Room Dress Uz4WzX1 & trexyourex.com | 2018
John J. Miles; Mai Ping Tan; Garry Dolton; Sarah A.E. Galloway; Bruno Laugel; Mathew Clement; Julia Makinde; Kristin Ladell; Katherine K. Matthews; Thomas S. Watkins; Katie Tungatt; Yide Wong; Han Siean Lee; Richard J. Clark; Johanne M. Pentier; Meriem Attaf; Anya Lissina; Ann Ager; Awen Gallimore; Pierre J. Rizkallah; Stephanie Gras; Jamie Rossjohn; Scott R. Burrows; David K. Cole; David A. Price; Andrew K. Sewell
Polypeptide vaccines effectively activate human T cells but suffer from poor biological stability, which confines both transport logistics and in vivo therapeutic activity. Synthetic biology has the potential to address these limitations through the generation of highly stable antigenic “mimics” using subunits that do not exist in the natural world. We developed a platform based on D–amino acid combinatorial chemistry and used this platform to reverse engineer a fully artificial CD8+ T cell agonist that mirrored the immunogenicity profile of a native epitope blueprint from influenza virus. This nonnatural peptide was highly stable in human serum and gastric acid, reflecting an intrinsic resistance to physical and enzymatic degradation. In vitro, the synthetic agonist stimulated and expanded an archetypal repertoire of polyfunctional human influenza virus–specific CD8+ T cells. In vivo, specific responses were elicited in naive humanized mice by subcutaneous vaccination, conferring protection from subsequent lethal influenza challenge. Moreover, the synthetic agonist was immunogenic after oral administration. This proof-of-concept study highlights the power of synthetic biology to expand the horizons of vaccine design and therapeutic delivery.
Turtleneck Chelsea28 Layering Layering Chelsea28 Chelsea28 Turtleneck HqP4wO7 & trexyourex.com | 2018
John J. Miles; Mai Ping Tan; Garry Dolton; Sarah A.E. Galloway; Bruno Laugel; Mathew Clement; Julia Makinde; Kristin Ladell; Katherine K. Matthews; Thomas S. Watkins; Katie Tungatt; Yide Wong; Han Siean Lee; Richard J. Clark; Johanne M. Pentier; Meriem Attaf; Anya Lissina; Ann Ager; Awen Gallimore; Pierre J. Rizkallah; Stephanie Gras; Jamie Rossjohn; Scott R. Burrows; David K. Cole; David A. Price; Andrew K. Sewell
Polypeptide vaccines effectively activate human T cells but suffer from poor biological stability, which confines both transport logistics and in vivo therapeutic activity. Synthetic biology has the potential to address these limitations through the generation of highly stable antigenic “mimics” using subunits that do not exist in the natural world. We developed a platform based on D–amino acid combinatorial chemistry and used this platform to reverse engineer a fully artificial CD8+ T cell agonist that mirrored the immunogenicity profile of a native epitope blueprint from influenza virus. This nonnatural peptide was highly stable in human serum and gastric acid, reflecting an intrinsic resistance to physical and enzymatic degradation. In vitro, the synthetic agonist stimulated and expanded an archetypal repertoire of polyfunctional human influenza virus–specific CD8+ T cells. In vivo, specific responses were elicited in naive humanized mice by subcutaneous vaccination, conferring protection from subsequent lethal influenza challenge. Moreover, the synthetic agonist was immunogenic after oral administration. This proof-of-concept study highlights the power of synthetic biology to expand the horizons of vaccine design and therapeutic delivery.